Fig. 4From: Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphomaProgression-free survival (PFS, a) and overall survival (OS, b) of all patients that received rituximab during induction chemotherapy (N = 45) treated either with (N = 24) or without (N = 21) rituximab maintenance therapy. Median PFS and OS not reachedBack to article page